Industry News
HPV vaccination not linked with risky sexual behavior among teenage girls
Dec 09, 2014
Sexual behavior of teenage girls does not appear to be affected by routine human papilloma virus vaccination, according to a large study published in CMAJ. Read More
Breast density notification laws substantially increase costs yet save few lives
Dec 08, 2014
Laws requiring supplemental ultrasound screening for women with dense breasts would substantially increase costs and save relatively few lives, according to an article published in Annals of... Read More
Tramadol associated with increased risk of hospitalization for hypoglycemia
Dec 08, 2014
The opioid pain-reliever tramadol appears to be associated with an increased risk of hospitalization for hypoglycemia, a potentially fatal condition caused by low blood sugar, according to a report... Read More
Hodgkin lymphoma responds to immunotherapy
Dec 08, 2014
Two trials show promising results in Hodgkin lymphoma patients treated with immunotherapy drugs that helped their immune system recognize and attack their blood cancer. Read More
Scientists pinpoint a new line of defence used by cancer cells
Dec 08, 2014
Cancer Research UK scientists have discovered a new line of defence used by cancer cells to evade cell death, according to research published in Nature Communications* today (Monday). Read More
Tasman divide remains in cancer survival
Dec 08, 2014
The latest systematic comparison of cancer survival between Australia and New Zealand shows more than 750 New Zealanders who die of cancer each year would survive if they lived on the other side of... Read More
VAXIMM reports positive follow-on data from oral cancer vaccine trial
Dec 08, 2014
VAXIMM AG, a Swiss-German biotech company focusing on oral cancer vaccines, announced today follow-on data from the first clinical trial of its investigational oral T-cell vaccine VXM01. Read More
First and only treatment for multicentric Castleman's disease, SYLVANT, now approved in Canada
Dec 08, 2014
Janssen Inc. has announced that Health Canada has approved SYLVANTTM (siltuximab) for the treatment of patients with multicentric Castleman's disease (MCD) who are human immunodeficiency virus... Read More
FDA approves Jakafi to treat patients with a chronic type of bone marrow disease
Dec 08, 2014
The U.S. Food and Drug Administration have approved a new use for Jakafi (ruxolitinib) to treat patients with polycythemia vera, a chronic type of bone marrow disease. Read More
Xtandi™ (enzalutamide) now licensed for use in the UK to treat men with advanced prostate cancer, following initial hormone treatment failure
Dec 08, 2014
XTANDI TM(enzalutamide) is now licensed in Europe and is already funded in England on the Cancer Drugs Fund,2 for the treatment of adult men with metastatic castration-resistant prostate cancer... Read More
Previous Page Next Page